Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurogastroenterol Motil ; 25(5): e339-52, 2013 May.
Article in English | MEDLINE | ID: mdl-23551931

ABSTRACT

BACKGROUND: Soluble guanylate cyclase (sGC) is the principal target of nitric oxide (NO) to control gastrointestinal motility. The consequence on nitrergic signaling and gut motility of inducing a heme-free status of sGC, as induced by oxidative stress, was investigated. METHODS: sGCß1 (H105F) knock-in (apo-sGC) mice, which express heme-free sGC that has basal activity, but cannot be stimulated by NO, were generated. KEY RESULTS: Diethylenetriamine NONOate did not increase sGC activity in gastrointestinal tissue of apo-sGC mice. Exogenous NO did not induce relaxation in fundic, jejunal and colonic strips, and pyloric rings of apo-sGC mice. The stomach was enlarged in apo-sGC mice with hypertrophy of the muscularis externa of the fundus and pylorus. In addition, gastric emptying and intestinal transit were delayed and whole-gut transit time was increased in the apo-sGC mice, while distal colonic transit time was maintained. The nitrergic relaxant responses to electrical field stimulation at 1-4 Hz were abolished in fundic and jejunal strips from apo-sGC mice, but in pyloric rings and colonic strips, only the response at 1 Hz was abolished, indicating the contribution of other transmitters than NO. CONCLUSIONS & INFERENCES: The results indicate that the gastrointestinal consequences of switching from a native sGC to a heme-free sGC, which cannot be stimulated by NO, are most pronounced at the level of the stomach establishing a pivotal role of the activation of sGC by NO in normal gastric functioning. In addition, delayed intestinal transit was observed, indicating that nitrergic activation of sGC also plays a role in the lower gastrointestinal tract.


Subject(s)
Gastrointestinal Motility/physiology , Gastroparesis/metabolism , Guanylate Cyclase/metabolism , Heme/deficiency , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Disease Models, Animal , Gastric Mucosa/metabolism , Gene Knock-In Techniques , Guanylate Cyclase/chemistry , Mice , Nitric Oxide/metabolism , Nitric Oxide/pharmacology , Oxidative Stress/physiology , Receptors, Cytoplasmic and Nuclear/chemistry , Soluble Guanylyl Cyclase
2.
Neurogastroenterol Motil ; 22(5): 557-63, e121-2, 2010 May.
Article in English | MEDLINE | ID: mdl-20025676

ABSTRACT

BACKGROUND: The 5-HT(4) receptor agonist prucalopride enhances large intestinal contractility by facilitating acetylcholine release through activation of 5-HT(4) receptors on cholinergic nerves and is effective in patients with constipation. Patients with intestinal endometriosis can present with constipation. We investigated in vitro whether large intestinal endometriotic infiltration influences contractility and facilitation of acetylcholine release by prucalopride. METHODS: Sigmoid colon or rectum circular muscle strips were obtained at the level of an endometriotic nodule with infiltration of the Auerbach plexus, and at a macroscopically healthy site at least 5 cm cranially from the nodule, in patients undergoing laparoscopic colorectal resection because of symptomatic bowel endometriosis. Responses to muscarinic receptor stimulation and to electrical field stimulation (EFS), and the facilitating effect of prucalopride on acetylcholine release were evaluated. KEY RESULTS: The EC50 and E(max) of the contractile responses to the muscarinic receptor agonist carbachol did not differ between healthy and lesioned strips. EFS-induced on-contractions were not different between the healthy and lesioned strips, while the non-nitrergic relaxant responses induced by EFS were decreased in the lesioned strips. The facilitating effect of prucalopride on acetylcholine release in healthy strips was similar to that reported before in macroscopically healthy colon tissue of patients with colon cancer; in lesioned strips, the effect of prucalopride was fully maintained in 6/8 patients and absent in two. CONCLUSIONS & INFERENCES: Large intestinal endometriosis does not lead to a systematic interference with the cholinergic facilitating effect of prucalopride.


Subject(s)
Acetylcholine/metabolism , Endometriosis/metabolism , Intestinal Diseases/metabolism , Intestine, Large/metabolism , Receptors, Serotonin, 5-HT4/metabolism , Adult , Area Under Curve , Benzofurans/pharmacology , Electric Stimulation , Female , Humans , Intestine, Large/drug effects , Middle Aged , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth/drug effects , Muscle, Smooth/metabolism , Serotonin Receptor Agonists/pharmacology , Signal Processing, Computer-Assisted
SELECTION OF CITATIONS
SEARCH DETAIL
...